CA2537057A1 - Cancer treatment with epothilones - Google Patents

Cancer treatment with epothilones Download PDF

Info

Publication number
CA2537057A1
CA2537057A1 CA002537057A CA2537057A CA2537057A1 CA 2537057 A1 CA2537057 A1 CA 2537057A1 CA 002537057 A CA002537057 A CA 002537057A CA 2537057 A CA2537057 A CA 2537057A CA 2537057 A1 CA2537057 A1 CA 2537057A1
Authority
CA
Canada
Prior art keywords
treatment
pharmaceutical preparation
epothilone
proliferative disease
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002537057A
Other languages
English (en)
French (fr)
Inventor
Clifford Dilea
Paul M. J. Mcsheehy
Sauveur-Michel Maira
Chiaki Tanaka
Markus Wartmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2537057A1 publication Critical patent/CA2537057A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CA002537057A 2003-09-02 2004-09-01 Cancer treatment with epothilones Abandoned CA2537057A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49954803P 2003-09-02 2003-09-02
US60/499,548 2003-09-02
PCT/EP2004/009737 WO2005020989A1 (en) 2003-09-02 2004-09-01 Cancer treatment with epothilones

Publications (1)

Publication Number Publication Date
CA2537057A1 true CA2537057A1 (en) 2005-03-10

Family

ID=34272839

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002537057A Abandoned CA2537057A1 (en) 2003-09-02 2004-09-01 Cancer treatment with epothilones

Country Status (9)

Country Link
US (2) US20060235059A1 (https=)
EP (1) EP1663214A1 (https=)
JP (1) JP2007504259A (https=)
CN (1) CN1870995A (https=)
AU (1) AU2004268377B2 (https=)
BR (1) BRPI0414043A (https=)
CA (1) CA2537057A1 (https=)
MX (1) MXPA06002393A (https=)
WO (1) WO2005020989A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1640004A1 (en) * 2004-09-24 2006-03-29 Schering Aktiengesellschaft Use of epothilones in the treatment of bone metastases and bone tumors or cancers
CN100384419C (zh) * 2005-12-02 2008-04-30 菏泽睿鹰制药集团有限公司 一种埃坡霉素缓释植入组合物及应用
EA020954B1 (ru) 2008-06-16 2015-03-31 Бинд Терапьютикс, Инк. Загруженные лекарственным средством полимерные наночастицы, фармацевтическая композиция и способ лечения рака
WO2010005726A2 (en) 2008-06-16 2010-01-14 Bind Biosciences Inc. Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
US8318211B2 (en) 2008-06-16 2012-11-27 Bind Biosciences, Inc. Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same
US8563041B2 (en) 2008-12-12 2013-10-22 Bind Therapeutics, Inc. Therapeutic particles suitable for parenteral administration and methods of making and using same
JP2012512175A (ja) 2008-12-15 2012-05-31 バインド バイオサイエンシズ インコーポレイテッド 治療薬を徐放するための長時間循環性ナノ粒子
DK2509634T3 (en) 2009-12-11 2019-04-23 Pfizer Stable formulations for lyophilization of therapeutic particles
EP2515942B1 (en) 2009-12-15 2020-02-12 Pfizer Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
WO2011084521A2 (en) * 2009-12-15 2011-07-14 Bind Biosciences, Inc. Therapeutic polymeric nanoparticles comprising epothilone and methods of making and using same
WO2014043618A1 (en) 2012-09-17 2014-03-20 Bind Therapeutics, Inc. Process for preparing therapeutic nanoparticles
PE20170312A1 (es) 2014-03-14 2017-03-30 Pfizer Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820269A (en) * 1983-03-07 1989-04-11 Vanderbilt University Mixer apparatus for controlling intravenous drug infusion
US5968972A (en) * 1995-10-26 1999-10-19 Baker Norton Pharmaceuticals, Inc. Method for increasing the oral bioactivity of pharmaceutical agents
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
ES2304240T3 (es) * 2001-01-25 2008-10-01 Bristol-Myers Squibb Company Procedimientos para la preparacion de preparaciones farmaceuticas que contienen analogos de epotilona para el tratamiento de cancer.
IL157443A0 (en) * 2001-03-14 2004-03-28 Bristol Myers Squibb Co Pharmaceutical compositions for the treatment of cancer including an epothilone analog and a chemotherapeutic agent
TWI287986B (en) * 2001-12-13 2007-10-11 Novartis Ag Use of Epothilones for the treatment of the carcinoid syndrome
MXPA04006822A (es) * 2002-01-14 2004-12-08 Novartis Ag Combinaciones que comprenden epotilonas y anti-metabolitos.
EP1503756B1 (en) * 2002-05-01 2009-08-12 Novartis AG Epothilone derivative for the treatment of hepatoma and other cancer diseases
CN101389334A (zh) * 2002-05-20 2009-03-18 高山生物科学股份有限公司 埃坡霉素d的给药方法
BR0313198A (pt) * 2002-08-02 2005-07-12 Novartis Ag Derivados de epotilona
BR0317150A (pt) * 2002-12-09 2005-11-01 Novartis Ag Estabilizadores de microtúbulos em stents para o tratamento de estenose
BRPI0412000A (pt) * 2003-06-27 2006-08-15 Novartis Ag tratamento de cáncer com epotilonas

Also Published As

Publication number Publication date
US20060235059A1 (en) 2006-10-19
MXPA06002393A (es) 2006-06-20
EP1663214A1 (en) 2006-06-07
JP2007504259A (ja) 2007-03-01
AU2004268377B2 (en) 2008-06-26
US20090069394A1 (en) 2009-03-12
CN1870995A (zh) 2006-11-29
BRPI0414043A (pt) 2006-10-24
WO2005020989A1 (en) 2005-03-10
AU2004268377A1 (en) 2005-03-10

Similar Documents

Publication Publication Date Title
US20090069394A1 (en) Cancer treatment with epothilones
AU755944B2 (en) Use of epothilones for the treatment of cancer
US6302838B1 (en) Cancer treatment with epothilones
EP1052974B1 (en) Pharmaceutical formulation containing epothilone
JP2002504511A5 (https=)
US20170232017A1 (en) Treatment of cancer
RU2358730C2 (ru) Производное эпотилона для лечения гепатомы и других раковых заболеваний
AU2004251444B2 (en) Cancer treatment with epothilones
RU2242229C2 (ru) Применение эпотилонов для лечения рака
AU2003202508B2 (en) Use of epothilones for the treatment of cancer
WO2019106424A1 (en) Dianhydrogalactitol for the treatment of diffuse intrinsic pontine gliomas
ES2354193T3 (es) Utilización de epotilonas para el tratamiento del cáncer.
JP2006518355A (ja) インドロピロロカルバゾール誘導体及び他の抗腫瘍薬を含む併用療法
HK1033809B (en) Pharmaceutical formulation containing epothilone
HK1073601B (en) Epothilone derivative for the treatment of hepatoma and other cancer diseases

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued